Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced that it has received clinical clearance from the U.S. Food and Drug Administration (FDA) for its TNFR2-targeted monoclonal antibody (mAb), SBT-1901, for the treatment of locally advanced or metastatic solid tumors.
Preclinical studies have demonstrated that SBT-1901 shows significant anti-tumor activity, both as a standalone therapy and in combination with anti-PD-1 antibodies. Notably, there is no equivalent product currently available on the global market, with the most advanced similar product being in Phase II clinical development.- Flcube.com
